It will be interesting in future work to investigate the effects of nondegrader BCL6 BTB–POZ domain inhibitors on DLBCL cells that are likely to be more representative of primary human tumors such as patient-derived xenograft models. Here, BCL6 is linked to diffuse large B-cell lymphoma.